0 19

Cited 0 times in

Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study)

Authors
 Cho, Sung Yong  ;  Jeong, Seong Jin  ;  Lee, Sangchul  ;  Kim, Janghwan  ;  Lee, Seong Ho  ;  Choo, Min Soo  ;  Oh, Seung-June 
Citation
 NEUROUROLOGY AND URODYNAMICS, v.40, no.1, pp.286 - 294 
Journal Title
 NEUROUROLOGY AND URODYNAMICS 
ISSN
 0733-2467 
Issue Date
2021-01
Keywords
mirabegron ; overactive ; Parkinson disease ; Parkinsonian disorders ; patient satisfaction ; urinary bladder
Abstract
Aims This study aimed to investigate the efficacy and safety of mirabegron for Parkinsonism patients with overactive bladder (OAB) symptoms in a randomized, placebo-controlled, multicenter study. Materials and Methods Inclusion criteria are Parkinsonism with OAB symptoms for 4 weeks or more, OAB symptom score (OABSS) questionnaire scores greater than 2, and OABSS urgency question scores greater than 1. After a 2-week wash-out period, the patients were randomized into placebo and mirabegron groups at visit 2. Visit 3 was performed after 4 weeks of medication. Mirabegron was prescribed to the two groups for the rest of the study period at visit 4. Result The mean age was 68.1 +/- 8.1 years and 72 males and 64 females were included. A total of 136 patients were screened, 117 patients were randomized, and 25 patients dropped out. The OABSS scores were significantly different between the two groups at Weeks 4 and 8. The OABSS scores became the same in the two groups at Week 12 (visit 5). The postvoid residual urine volume showed a mild increase to 64 ml in the mirabegron group compared to the placebo group at visit 4. Adverse events occurred in 27 patients (23.1%). The degree was mild in 26 cases (78.8%), moderate in five (15.2%), and severe in two (6.1%). Only 13 cases (39.4%) showed medication-related adverse events. Acute urinary retention occurred in a single case. The treatment satisfaction questionnaires showed no significant differences between the two groups. Conclusion Mirabegron was effective in treating OAB symptoms in patients with Parkinsonism with acceptable adverse events.
DOI
10.1002/nau.24552
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jang Hwan(김장환) ORCID logo https://orcid.org/0000-0002-9056-7072
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/181880
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links